Aeterna Zentaris unveils AEZS-108 study results
In the trial, patients received a recommended dose of 267mg/m2 by intravenous infusion over 2 hours, with retreatment every 3 weeks, for up to 6 courses. Aeterna Zentaris
China-based clinical-stage biotechnology company BoomRay Pharmaceuticals and Novartis Pharma have signed an exclusive worldwide licence deal for an undisclosed preclinical radioligand therapy (RLT) asset in a deal worth up to $900m.